random-effects generalized least squares regression model stata 7.0 Search Results


xtreg procedure  (STATA Corporation)
99
STATA Corporation xtreg procedure
Xtreg Procedure, supplied by STATA Corporation, used in various techniques. Bioz Stars score: 99/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/random-effects+generalized+least+squares+regression+model+stata+7%2E0/STATA+7%2E0/pmc01761927-110-24-27
Average 99 stars, based on 1 article reviews
xtreg procedure - by Bioz Stars, 2026-09
99/100 stars
  Buy from Supplier
stata statistical software  (STATA Corporation)
99
STATA Corporation stata statistical software
Stata Statistical Software, supplied by STATA Corporation, used in various techniques. Bioz Stars score: 99/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/random-effects+generalized+least+squares+regression+model+stata+7%2E0/STATA+1%2E0/pm11807777-63-17-17
Average 99 stars, based on 1 article reviews
stata statistical software - by Bioz Stars, 2026-09
99/100 stars
  Buy from Supplier
cogstate test battery  (CogState Ltd)
90
CogState Ltd cogstate test battery
Cogstate Test Battery, supplied by CogState Ltd, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/random-effects+generalized+least+squares+regression+model+stata+7%2E0/cogstate+battery/pmc06494563-2517-255-259
Average 90 stars, based on 1 article reviews
cogstate test battery - by Bioz Stars, 2026-09
90/100 stars
  Buy from Supplier
scanner siemens skyra  (Siemens AG)
90
Siemens AG scanner siemens skyra
Scanner Siemens Skyra, supplied by Siemens AG, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/random-effects+generalized+least+squares+regression+model+stata+7%2E0/32+channel+head+coil/pmc12056726__fcaf152_supplementary_data-130-142-144
Average 90 stars, based on 1 article reviews
scanner siemens skyra - by Bioz Stars, 2026-09
90/100 stars
  Buy from Supplier
xsl-fo  (RenderX Inc)
90
RenderX Inc xsl-fo
Xsl Fo, supplied by RenderX Inc, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/random-effects+generalized+least+squares+regression+model+stata+7%2E0/xsl%E2%80%A2fo/pm37261900-125-45-13
Average 90 stars, based on 1 article reviews
xsl-fo - by Bioz Stars, 2026-09
90/100 stars
  Buy from Supplier
sars cov 2 spike protein  (Gilead Sciences)
99
Gilead Sciences sars cov 2 spike protein
Panel A shows the adjusted mean change in viral load from baseline among all the patients who received at least one dose of the drug or placebo, had at least one visit between day 1 and day 28, did not receive or were not expected at baseline to receive Covid-19 therapeutic monoclonal antibody treatment, and were treated within 3 days after the onset of Covid-19 (modified intention-to-treat population). Panel B shows findings for the subgroup of patients whose baseline <t>SARS-CoV-2</t> serology status was negative, and Panel C shows findings for the subgroup of patients whose baseline SARS-CoV-2 serology status was positive. Panel D shows findings among patients whose baseline viral load was more than 10 4 copies per milliliter, and Panel E shows findings among patients whose baseline viral load was more than 10 7 copies per milliliter. Patients were excluded from the analysis if the viral load was not detected or if data on baseline viral load were missing. Results obtained with unvalidated swabs were also excluded. Results were obtained with the use of a mixed-effects repeated-measures analysis of covariance model. Treatment, visit, and visit-by-treatment interactions were fixed effects in the analysis. Geographic region, baseline SARS-CoV-2 serology status, baseline viral load, and nasopharyngeal sample site were covariates, and participant was a random effect.
Sars Cov 2 Spike Protein, supplied by Gilead Sciences, used in various techniques. Bioz Stars score: 99/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/random-effects+generalized+least+squares+regression+model+stata+7%2E0/VEKLURY/pmc08908851-132-89-93
Average 99 stars, based on 1 article reviews
sars cov 2 spike protein - by Bioz Stars, 2026-09
99/100 stars
  Buy from Supplier
bmj open  (CH Instruments)
90
CH Instruments bmj open
Panel A shows the adjusted mean change in viral load from baseline among all the patients who received at least one dose of the drug or placebo, had at least one visit between day 1 and day 28, did not receive or were not expected at baseline to receive Covid-19 therapeutic monoclonal antibody treatment, and were treated within 3 days after the onset of Covid-19 (modified intention-to-treat population). Panel B shows findings for the subgroup of patients whose baseline <t>SARS-CoV-2</t> serology status was negative, and Panel C shows findings for the subgroup of patients whose baseline SARS-CoV-2 serology status was positive. Panel D shows findings among patients whose baseline viral load was more than 10 4 copies per milliliter, and Panel E shows findings among patients whose baseline viral load was more than 10 7 copies per milliliter. Patients were excluded from the analysis if the viral load was not detected or if data on baseline viral load were missing. Results obtained with unvalidated swabs were also excluded. Results were obtained with the use of a mixed-effects repeated-measures analysis of covariance model. Treatment, visit, and visit-by-treatment interactions were fixed effects in the analysis. Geographic region, baseline SARS-CoV-2 serology status, baseline viral load, and nasopharyngeal sample site were covariates, and participant was a random effect.
Bmj Open, supplied by CH Instruments, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/random-effects+generalized+least+squares+regression+model+stata+7%2E0/bmj+open/pmc08126284__bmjopen___2020___045992__draft_revisions-126-267-255
Average 90 stars, based on 1 article reviews
bmj open - by Bioz Stars, 2026-09
90/100 stars
  Buy from Supplier
kristensen 2008  (Natan GmbH)
90
Natan GmbH kristensen 2008
Panel A shows the adjusted mean change in viral load from baseline among all the patients who received at least one dose of the drug or placebo, had at least one visit between day 1 and day 28, did not receive or were not expected at baseline to receive Covid-19 therapeutic monoclonal antibody treatment, and were treated within 3 days after the onset of Covid-19 (modified intention-to-treat population). Panel B shows findings for the subgroup of patients whose baseline <t>SARS-CoV-2</t> serology status was negative, and Panel C shows findings for the subgroup of patients whose baseline SARS-CoV-2 serology status was positive. Panel D shows findings among patients whose baseline viral load was more than 10 4 copies per milliliter, and Panel E shows findings among patients whose baseline viral load was more than 10 7 copies per milliliter. Patients were excluded from the analysis if the viral load was not detected or if data on baseline viral load were missing. Results obtained with unvalidated swabs were also excluded. Results were obtained with the use of a mixed-effects repeated-measures analysis of covariance model. Treatment, visit, and visit-by-treatment interactions were fixed effects in the analysis. Geographic region, baseline SARS-CoV-2 serology status, baseline viral load, and nasopharyngeal sample site were covariates, and participant was a random effect.
Kristensen 2008, supplied by Natan GmbH, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/random-effects+generalized+least+squares+regression+model+stata+7%2E0/kristensen+2008/10__1002_slash_14651858__cd003474__pub4-2151-197-209
Average 90 stars, based on 1 article reviews
kristensen 2008 - by Bioz Stars, 2026-09
90/100 stars
  Buy from Supplier
nsabp-34 2012  (NSABP Foundation)
90
NSABP Foundation nsabp-34 2012
Panel A shows the adjusted mean change in viral load from baseline among all the patients who received at least one dose of the drug or placebo, had at least one visit between day 1 and day 28, did not receive or were not expected at baseline to receive Covid-19 therapeutic monoclonal antibody treatment, and were treated within 3 days after the onset of Covid-19 (modified intention-to-treat population). Panel B shows findings for the subgroup of patients whose baseline <t>SARS-CoV-2</t> serology status was negative, and Panel C shows findings for the subgroup of patients whose baseline SARS-CoV-2 serology status was positive. Panel D shows findings among patients whose baseline viral load was more than 10 4 copies per milliliter, and Panel E shows findings among patients whose baseline viral load was more than 10 7 copies per milliliter. Patients were excluded from the analysis if the viral load was not detected or if data on baseline viral load were missing. Results obtained with unvalidated swabs were also excluded. Results were obtained with the use of a mixed-effects repeated-measures analysis of covariance model. Treatment, visit, and visit-by-treatment interactions were fixed effects in the analysis. Geographic region, baseline SARS-CoV-2 serology status, baseline viral load, and nasopharyngeal sample site were covariates, and participant was a random effect.
Nsabp 34 2012, supplied by NSABP Foundation, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/random-effects+generalized+least+squares+regression+model+stata+7%2E0/nsabp+34+2012/10__1002_slash_14651858__cd003474__pub4-2151-119-298
Average 90 stars, based on 1 article reviews
nsabp-34 2012 - by Bioz Stars, 2026-09
90/100 stars
  Buy from Supplier
azure 2014  (Natan GmbH)
90
Natan GmbH azure 2014
Panel A shows the adjusted mean change in viral load from baseline among all the patients who received at least one dose of the drug or placebo, had at least one visit between day 1 and day 28, did not receive or were not expected at baseline to receive Covid-19 therapeutic monoclonal antibody treatment, and were treated within 3 days after the onset of Covid-19 (modified intention-to-treat population). Panel B shows findings for the subgroup of patients whose baseline <t>SARS-CoV-2</t> serology status was negative, and Panel C shows findings for the subgroup of patients whose baseline SARS-CoV-2 serology status was positive. Panel D shows findings among patients whose baseline viral load was more than 10 4 copies per milliliter, and Panel E shows findings among patients whose baseline viral load was more than 10 7 copies per milliliter. Patients were excluded from the analysis if the viral load was not detected or if data on baseline viral load were missing. Results obtained with unvalidated swabs were also excluded. Results were obtained with the use of a mixed-effects repeated-measures analysis of covariance model. Treatment, visit, and visit-by-treatment interactions were fixed effects in the analysis. Geographic region, baseline SARS-CoV-2 serology status, baseline viral load, and nasopharyngeal sample site were covariates, and participant was a random effect.
Azure 2014, supplied by Natan GmbH, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/random-effects+generalized+least+squares+regression+model+stata+7%2E0/azure+2014/10__1002_slash_14651858__cd003474__pub4-2151-173-209
Average 90 stars, based on 1 article reviews
azure 2014 - by Bioz Stars, 2026-09
90/100 stars
  Buy from Supplier
gain 2013  (Natan GmbH)
90
Natan GmbH gain 2013
Panel A shows the adjusted mean change in viral load from baseline among all the patients who received at least one dose of the drug or placebo, had at least one visit between day 1 and day 28, did not receive or were not expected at baseline to receive Covid-19 therapeutic monoclonal antibody treatment, and were treated within 3 days after the onset of Covid-19 (modified intention-to-treat population). Panel B shows findings for the subgroup of patients whose baseline <t>SARS-CoV-2</t> serology status was negative, and Panel C shows findings for the subgroup of patients whose baseline SARS-CoV-2 serology status was positive. Panel D shows findings among patients whose baseline viral load was more than 10 4 copies per milliliter, and Panel E shows findings among patients whose baseline viral load was more than 10 7 copies per milliliter. Patients were excluded from the analysis if the viral load was not detected or if data on baseline viral load were missing. Results obtained with unvalidated swabs were also excluded. Results were obtained with the use of a mixed-effects repeated-measures analysis of covariance model. Treatment, visit, and visit-by-treatment interactions were fixed effects in the analysis. Geographic region, baseline SARS-CoV-2 serology status, baseline viral load, and nasopharyngeal sample site were covariates, and participant was a random effect.
Gain 2013, supplied by Natan GmbH, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/random-effects+generalized+least+squares+regression+model+stata+7%2E0/gain+2013/10__1002_slash_14651858__cd003474__pub4-2151-185-209
Average 90 stars, based on 1 article reviews
gain 2013 - by Bioz Stars, 2026-09
90/100 stars
  Buy from Supplier
vandetanib  (AstraZeneca ltd)
90
AstraZeneca ltd vandetanib
Panel A shows the adjusted mean change in viral load from baseline among all the patients who received at least one dose of the drug or placebo, had at least one visit between day 1 and day 28, did not receive or were not expected at baseline to receive Covid-19 therapeutic monoclonal antibody treatment, and were treated within 3 days after the onset of Covid-19 (modified intention-to-treat population). Panel B shows findings for the subgroup of patients whose baseline <t>SARS-CoV-2</t> serology status was negative, and Panel C shows findings for the subgroup of patients whose baseline SARS-CoV-2 serology status was positive. Panel D shows findings among patients whose baseline viral load was more than 10 4 copies per milliliter, and Panel E shows findings among patients whose baseline viral load was more than 10 7 copies per milliliter. Patients were excluded from the analysis if the viral load was not detected or if data on baseline viral load were missing. Results obtained with unvalidated swabs were also excluded. Results were obtained with the use of a mixed-effects repeated-measures analysis of covariance model. Treatment, visit, and visit-by-treatment interactions were fixed effects in the analysis. Geographic region, baseline SARS-CoV-2 serology status, baseline viral load, and nasopharyngeal sample site were covariates, and participant was a random effect.
Vandetanib, supplied by AstraZeneca ltd, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/random-effects+generalized+least+squares+regression+model+stata+7%2E0/zd6474/10__1210_slash_jcem__96__1__9989-9-30-37
Average 90 stars, based on 1 article reviews
vandetanib - by Bioz Stars, 2026-09
90/100 stars
  Buy from Supplier

Image Search Results


Panel A shows the adjusted mean change in viral load from baseline among all the patients who received at least one dose of the drug or placebo, had at least one visit between day 1 and day 28, did not receive or were not expected at baseline to receive Covid-19 therapeutic monoclonal antibody treatment, and were treated within 3 days after the onset of Covid-19 (modified intention-to-treat population). Panel B shows findings for the subgroup of patients whose baseline SARS-CoV-2 serology status was negative, and Panel C shows findings for the subgroup of patients whose baseline SARS-CoV-2 serology status was positive. Panel D shows findings among patients whose baseline viral load was more than 10 4 copies per milliliter, and Panel E shows findings among patients whose baseline viral load was more than 10 7 copies per milliliter. Patients were excluded from the analysis if the viral load was not detected or if data on baseline viral load were missing. Results obtained with unvalidated swabs were also excluded. Results were obtained with the use of a mixed-effects repeated-measures analysis of covariance model. Treatment, visit, and visit-by-treatment interactions were fixed effects in the analysis. Geographic region, baseline SARS-CoV-2 serology status, baseline viral load, and nasopharyngeal sample site were covariates, and participant was a random effect.

Journal: The New England Journal of Medicine

Article Title: Oral Nirmatrelvir for High-Risk, Nonhospitalized Adults with Covid-19

doi: 10.1056/NEJMoa2118542

Figure Lengend Snippet: Panel A shows the adjusted mean change in viral load from baseline among all the patients who received at least one dose of the drug or placebo, had at least one visit between day 1 and day 28, did not receive or were not expected at baseline to receive Covid-19 therapeutic monoclonal antibody treatment, and were treated within 3 days after the onset of Covid-19 (modified intention-to-treat population). Panel B shows findings for the subgroup of patients whose baseline SARS-CoV-2 serology status was negative, and Panel C shows findings for the subgroup of patients whose baseline SARS-CoV-2 serology status was positive. Panel D shows findings among patients whose baseline viral load was more than 10 4 copies per milliliter, and Panel E shows findings among patients whose baseline viral load was more than 10 7 copies per milliliter. Patients were excluded from the analysis if the viral load was not detected or if data on baseline viral load were missing. Results obtained with unvalidated swabs were also excluded. Results were obtained with the use of a mixed-effects repeated-measures analysis of covariance model. Treatment, visit, and visit-by-treatment interactions were fixed effects in the analysis. Geographic region, baseline SARS-CoV-2 serology status, baseline viral load, and nasopharyngeal sample site were covariates, and participant was a random effect.

Article Snippet: Molnupiravir is an orally administered antiviral Covid-19 treatment that currently has emergency use authorization in the United States for use in the high-risk, nonhospitalized population, achieving a 30% reduction in Covid-19–related hospitalization or death through 29 days after randomization., Covid-19 therapeutic monoclonal antibodies are associated with relative risk reductions of approximately 70 to 85% against mild-to-moderate Covid-19 in outpatient settings ; however, monoclonal antibodies require intravenous or subcutaneous administration in a health care setting, and they may be less effective against emerging variants harboring mutations in the monoclonal antibody–targeted SARS-CoV-2 spike protein., , Remdesivir, an agent administered intravenously that is approved for use in patients hospitalized for Covid-19, has shown an 87% reduction in the risk of progression to severe disease in the outpatient setting.

Techniques: Modification